reports
- ABGSC Energy Research
- Daniel Vårdal Haugland
- Herman Caspersen
- John Olaisen
- Lars Trongaard Brattli
- Martin Mauseth
- Stian Wibstad
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in ...
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan New Patent Grants Broad Composition Claims for PDS0101 Previously Granted Patent Protections and Anticipated Market Exclusivity Provide Protection for PDS0101 in the United States into the 2040s PRINCETON, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Japan Patent Office has issued Patent No. 7783866 for PDS01...
Transocean Ltd. Announces $130 Million Award for Ultra-Deepwater Drill...
Transocean Ltd. Announces $130 Million Award for Ultra-Deepwater Drillship STEINHAUSEN, Switzerland, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) (“Transocean”) today announced the execution of a six-well contract in Australia with an undisclosed operator for the Deepwater Skyros. The estimated 320-day campaign is expected to commence in the first quarter of 2027 and contribute approximately $130 million in backlog, excluding compensation for mobilization and demobilization. The award includes priced options that, if fully exercised, could keep the drillship working in Au...
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and ...
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”) Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval Pathway PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that its request for a Type C Meeting with the FDA has been accepted by the agency, and the meeting has been scheduled to oc...
Transocean Ltd: 2 directors
Two Directors at Transocean Ltd sold 530,000 shares at between 4.290USD and 4.320USD. The significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
- Jonathan Moreland
TPC TUTOR PERINI CORPORATION
RPD RAPID7 INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
GLP GLOBAL PARTNERS LP
DIN DINE BRANDS GLOBAL INC.
RIGN TRANSOCEAN LTD.
AP AMPCO-PITTSBURGH
KYN KAYNE ANDERSON MLP INVESTMENT CO.
VVV VALVOLINE INC.
IIPR INNOVATIVE INDUSTRIAL PROPERTIES INC
MLP MAUI LAND & PINEAPPLE CO. INC.
GSHD GOOSEHEAD INSURANCE
VRCA VERRICA PHARMACEUTICALS
AEYE AUDIOEYE INC
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
UTZ UTZ BRANDS INC (A)
ABCL ABCELLERA BIOLOGICS
PBBK PB BANKSHARES
NEXT INC.
BBWI NEXT CAPITAL
EVLV BATH & BODY WORKS INC
ENOV EVOLV TECHNOLOGIES HLDGS INC
QDEL ENOVIS CORPORATION
J QUIDEL CORP
EBC JACOBS SOLUTIONS INC.
WEST EASTERN BANKSHARES INC
SMRT WESTROCK COFFEE COMPANY LLC
GTE SMARTRENT INC
MNR GRAN TIERRA ENERGY INC.
GAM MACH NATURAL RESOURCES LP
SPRU GENERAL DE ALQUILER DE MAQUINARIA
GF SPRUCE POWER HOLDING CORP
THE NEW GERMANY FUND
INC.
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Lars Trongaard Brattli
- Martin Mauseth
- Njål Kleiven
- Stian Wibstad
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TPC TUTOR PERINI CORPORATION
RPD RAPID7 INC.
POST POST HOLDINGS INC.
NWBI NORTHWEST BANCSHARES INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MMLP MARTIN MIDSTREAM PARTNERS L.P.
GLP GLOBAL PARTNERS LP
CALX CALIX NETWORKS
GAM GENERAL AMERICAN INVESTORS CO. INC.
PBI PITNEY BOWES INC.
RIGN TRANSOCEAN LTD.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
VVV VALVOLINE INC.
IIPR INNOVATIVE INDUSTRIAL PROPERTIES INC
PED PEDEVCO CORP
VRCA VERRICA PHARMACEUTICALS
ONEW ONEWATER MARINE
BBWI BATH & BODY WORKS INC
EVLV EVOLV TECHNOLOGIES HLDGS INC
QDEL QUIDEL CORP
J JACOBS SOLUTIONS INC.
EBC EASTERN BANKSHARES INC
SMRT SMARTRENT INC
GTE GRAN TIERRA ENERGY INC.
MNR MACH NATURAL RESOURCES LP
RMI RIVERNORTH OPPOR MUN INC FD INC
MacroGenics to Participate in the 8th Annual Evercore Healthcare Confe...
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, at 7:55 am ET in Miami, FL. A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section ...
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Lars Trongaard Brattli
- Martin Mauseth
- Njål Kleiven
- Stian Wibstad
Transocean Ltd. Announces Exercised Options Totaling $89 Million
Transocean Ltd. Announces Exercised Options Totaling $89 Million STEINHAUSEN, Switzerland, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) today announced contract fixtures for one ultra-deepwater drillship and two harsh environment semisubmersibles. In aggregate, the fixtures represent approximately $89 million in firm contract backlog. In Brazil, Petrobras exercised a 90-day option for the Deepwater Mykonos in direct continuation of its current program. The program is expected to contribute approximately $33 million in backlog. In Norway, a two-well option was exercised ...
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides ...
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer Phase 2 Results Lead Company to Seek Expedited Approval Pathway in OngoingVERSATILE-003 Phase 3 Trial Design Conference Call and Webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on tra...
MacroGenics Reports Third Quarter 2025 Financial Results and Provides ...
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platformRealigned pipeline priorities by ending development of lorigerlimab in prostate cancer while continuing development in ovarian cancerCash runway guidance extended into late 2027 ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on ...
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offe...
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering $5.3 million Upfront with up to an Additional $5.8 million of Aggregate Gross Proceeds upon the Cash Exercise in Full of Warrants PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that it has entered into a securities purchase agreement for the purchase and sale of 5,800,000 shares of common stock (or pre-funded ...
PDS Biotechnology Announces Translational Data Showing Strong Immunolo...
PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025 Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms natural killer (NK) cells to possess characteristics that make them more active in killing cancer cellsPDS01ADC promotes stem cell-like killer T cells and memory T cells that self-replicate and are therefore capable of potent and long-lasting anti-tumor activity PRINCETON, N.J., Nov. 10, 2025 (GLOBE...
MacroGenics to Participate in the Stifel 2025 Healthcare Conference
MacroGenics to Participate in the Stifel 2025 Healthcare Conference ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025, at 4:00 pm ET in New York, NY. A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section of Mac...
PDS Biotech Announces Conference Call and Webcast for Third Quarter 20...
PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the quarter ended September 30, 2025 and provide a clinical programs update on Thursday, November 13, 2025 at 8:00 am Eastern Time. Conference Call Details Date: November ...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Magnificent Seven's Turn to Shine We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass). We will maintain our bullish intermediate-term outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6200 (up from 6028-6059). Additionally, we discussed since our 10/14/25 Compass how our near-term bullish outlook remains intact as long as the SPX holds above 6550-6569, which coincided with the ...
TSLA TESLA INC
THC TENET HEALTHCARE CORPORATION
NVDA NVIDIA CORPORATION
HCA HCA HEALTHCARE INC
HAL HALLIBURTON COMPANY
GOOGL ALPHABET INC. CLASS A
CYH COMMUNITY HEALTH SYSTEMS INC.
MAGS MAGAL SECURITY SYSTEMS LTD.
RIGN TRANSOCEAN LTD.
AAPL APPLE INC.
SDRL SEADRILL LTD.
VAL VALARIS LTD
BORR BORR DRILLING LTD
ARKK ARK INNOVATION ETF
NE NOBLE CORP (NEW)
ARDT ARDENT HEALTH PARTNERS INC
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Lars Trongaard Brattli
- Martin Mauseth
- Njål Kleiven
- Stian Wibstad
ORSTED ORSTED
HEX HEXAGON COMPOSITES ASA
SOC SUBSEA 7 S.A.
DNO DNO ASA CLASS A
ODL ODFJELL DRILLING
AKSOO AKER SOLUTIONS ASA
RIGN TRANSOCEAN LTD.
IPCO INTERNATIONAL PETROLEUM CORP
OKEA OKEA
NOL NORTHERN OCEAN
VWS VESTAS WIND SYSTEMS
BORR BORR DRILLING LTD
DOFG DOF GROUP ASA
SDRL SEADRILL LTD
New Clinical and Translational Data on PDS Biotechnology’s Novel Inves...
New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting Three abstracts accepted for presentation, including one rapid oral abstract sessionPresentations to highlight ongoing clinical and translational research across PDS Biotechnology’s immunotherapy platforms PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transfo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.